Taiyuan/Datong, Late August 2026 — Huang Guo, Party Secretary and Commissioner of China’s National Medical Products Administration (NMPA), led a delegation to Shanxi Province to survey pharmaceutical industry development, urging region-specific cultivation of new quality productive forces and pushing for high-end, intelligent, and green upgrades across the generic drug and active pharmaceutical ingredient (API) sectors.

Policy Snapshot

Attribute	Detail
Official	Huang Guo, NMPA Party Secretary and Commissioner
Locations	Taiyuan, Datong, Shanxi Province
Participants	NMPA relevant departments; Shanxi, Hebei, Inner Mongolia, Liaoning, Shandong, Henan provincial drug regulators; pharmaceutical enterprise executives
Focus areas	Modern drug logistics; risk monitoring; TCM innovation; API digital transformation; generic drug quality
Key themes	New quality productive forces; high-end/intelligent/green development; TCM inheritance; centralized procurement quality

Inspection Focus

In Taiyuan, the delegation visited pharmaceutical enterprises, the Shanxi Provincial Drug Safety Risk Monitoring Center, and the first inspection branch of the Shanxi Provincial Medical Products Administration to review modern drug logistics infrastructure, safety risk monitoring and response protocols, and frontline regulatory operations.

In Datong, the team toured TCM and API production facilities, assessing progress on traditional medicine inheritance and innovation as well as digital and intelligent transformation initiatives across the manufacturing base.

Regional Coordination

During the visit, Huang convened a thematic symposium with drug regulatory officials from Hebei, Shanxi, Inner Mongolia, Liaoning, Shandong, and Henan provinces and regions, alongside enterprise representatives, to jointly study measures to advance high-quality development of generic drugs and APIs.

Key Directives

Huang outlined six strategic priorities:

• New quality productive forces — Develop pharma-specific new quality productive forces tailored to local conditions.
• Generic and API upgrades — Drive the sector toward high-end, intelligent, and green manufacturing; encourage adoption of international advanced technologies to improve formulation standards and expand high-end API supply capacity.
• TCM innovation — Support the inheritance and innovation of traditional Chinese medicine, including time-honored brands, authentic medicinal materials, and decoction pieces, broadening pathways for high-quality TCM development.
• Contract manufacturing oversight — Strengthen supervision of contract production and other critical links.
• Post-market change control — Strictly standardize post-approval change management to ensure quality and safety of centralized procurement selected products.
• Regulatory capacity — Consolidate education on correct performance views, focusing on “hidden merits” in regulatory capacity building and drug safety safeguards to support industry growth through efficient and rigorous oversight.

Market Impact Analysis

Huang’s emphasis on high-end API manufacturing and generic drug quality signals a policy pivot toward upgrading China’s pharmaceutical supply chain rather than pure cost reduction. The focus on “international advanced technology” for formulations suggests regulators will incentivize—through faster reviews or preferential procurement—domestic makers that meet global quality benchmarks, potentially narrowing the gap between Chinese generics and originator products.

The TCM directives reinforce Beijing’s dual-track strategy: modernizing traditional medicine through digital transformation while preserving heritage brands and authentic sourcing. For Shanxi and neighboring provinces, the nod to region-specific development creates opportunities for local TCM clusters and API hubs to attract targeted investment and policy support.

The warning on contract manufacturing and post-market changes, coupled with explicit mention of centralized procurement quality, underscores that volume-based purchasing gains will not come at the expense of safety. Manufacturers with weak change-control systems or reliance on outsourced production face heightened audit risk.

Forward-Looking Statement

Industry analysts expect the NMPA to roll out concrete support measures for high-end API and generic drug upgrades by late 2026 or early 2027, potentially including dedicated fast-track reviews for intelligent manufacturing retrofits and green technology adoption. The six-province coordination mechanism suggests a regional cluster approach to pharma quality improvement, with Shanxi positioned as a northern hub for API and TCM innovation. Companies operating in the covered provinces should prepare for intensified inspections of contract manufacturing sites and post-market change documentation, while TCM players should anticipate preferential policies for heritage brand certification and authentic material traceability systems.-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/yaowen/ypjgyw/ypyw/20260830133253164.html

Beijing, Aug 28, 2026 — China’s Center for Drug Evaluation (CDE) proposed adding a human bone marrow mesenchymal stem cell injection, developed by Jiuzhitang Meike (Beijing) Cell Technology Co., Ltd., to the “Care Program – Extension” pilot for rare disease innovative drug development, targeting autoimmune pulmonary alveolar proteinosis with a public comment deadline of Sept 4, 2026.

Program Snapshot

Attribute	Detail
Program	Care Program – Extension (Rare Disease Innovative Drug Development Incentive Pilot)
Product	Human Bone Marrow Mesenchymal Stem Cell Injection
Applicant	Jiuzhitang Meike (Beijing) Cell Technology Co., Ltd.
Indication	Autoimmune pulmonary alveolar proteinosis
Comment deadline	Sept 4, 2026
Contact	zhaona@cde.org.cn

Clinical Context

Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare autoimmune disorder characterized by the accumulation of surfactant-like material in the alveoli due to autoantibodies against granulocyte-macrophage colony-stimulating factor. The disease leads to progressive respiratory failure with limited treatment options beyond whole-lung lavage and, in severe cases, lung transplantation.

Market Impact Analysis

The inclusion of a mesenchymal stem cell (MSC) therapy in the Care Program – Extension marks a significant expansion of China’s rare disease pilot into advanced cell therapy modalities. Jiuzhitang Meike, a subsidiary of the traditional Chinese medicine giant Jiuzhitang, is leveraging its cell technology platform to address autoimmune pulmonary alveolar proteinosis—an ultra-rare interstitial lung disease with no approved pharmacologic cure in China.

For the regenerative medicine sector, the pilot entry signals CDE’s openness to cell-based immunomodulatory approaches for rare autoimmune conditions, potentially establishing a regulatory precedent for MSC therapies in pulmonary indications. The choice of aPAP as the target indication is clinically compelling: the disease affects an estimated few thousand patients in China, creating a clear orphan drug pathway, while the autoimmune etiology aligns with MSCs’ established anti-inflammatory and immunomodulatory mechanisms.

Jiuzhitang Meike’s involvement highlights the convergence of traditional Chinese medicine conglomerates with modern biotech, as established pharmaceutical players diversify into cell therapy through dedicated subsidiaries. The short one-week comment window suggests regulators view the application as aligned with the pilot’s eligibility criteria, with formal inclusion expected by mid-September 2026.

Forward-Looking Statement

Industry analysts expect the stem cell injection to advance into clinical trials under the pilot’s enhanced regulatory support framework, with Phase I/II studies potentially initiating by early 2027. Success in autoimmune pulmonary alveolar proteinosis could validate MSC therapy as a disease-modifying approach for rare interstitial lung diseases, opening pathways for indications such as idiopathic pulmonary fibrosis or other autoimmune-driven respiratory conditions. The pilot’s backing also reinforces China’s strategic commitment to building domestic cell therapy capabilities, reducing reliance on imported biologics for ultra-rare diseases. Final pilot inclusion is anticipated following the Sept 4 comment deadline, barring substantive objections.-China Health Reform Pulse

Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/c5e79f73a0617dc4c2f449ee7d580c00